Holiday Notification: Cayman Chemical will be closed Monday, May 28, 2012, in observance of the Memorial Day holiday.
More…
Please feel free to continue placing orders via our website or via fax at 734-971-3640. You may send an email to customer service at custserv@caymanchem.com , or to technical support at techserv@caymanchem.com which we will respond to the next business day. Cayman will resume regular business hours and shipping schedules on Tuesday, May 29, 2012. Thank you for your patience and understanding.
SR 144528 is a selective peripheral cannabinoid (CB2) receptor inverse agonist that displays a Ki value of 0.6 nM for rat spleen and human recombinant CB2 receptors and a Ki value of 400 nM for rat brain and human recombinant CB1 receptors.1,2 SR 144528 antagonizes the inhibitory effects of CP 55,940 on forskolin-induced adenylyl cyclase activity in CHO cells expressing hCB2 (IC50 = 10 nM) but not in cells expressing hCB1 (IC50 > 10 µM).1 SR 144528 has been used to investigate the contribution of the CB2 receptor in the control of pain initiation as well as suppression of inflammation and immune activation.3,4,5,6
1
Rinaldi-Carmona, M., Barth, F., Millan, J., et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther284(2)644-650(1998).
2
Portier, M., Rinaldi-Carmona, M., Pecceu, F., et al. SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist. J Pharmacol Exp Ther288(2)582-589(1999).
3
Barth, F., and Rinaldi-Carmona, M. The development of cannabinoid antagonists. Curr Med Chem6745-755(1999).
4
Di Marzo, V. Targeting the endocannabinoid system: To enhance or reduce?Nat Rev Drug Discov7438-455(2008).
5
Iwamura, H., Suzuki, H., Ueda, Y., et al. In vitro and in vivo pharmacological characterization of JTE-907, a novel selection ligand for cannabinoid CB2 receptor. J Pharmacol Exp Ther296(2)420-425(2001).
6
Wright, K.L., Duncan, M., and Sharkey, K.A. Cannabinoid CB2 receptors in the gastrointestinal tract: A regulatory system in states of inflammation. Br J Pharmacol153263-270(2008).
Rinaldi-Carmona, M., Barth, F., Millan, J., et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther284(2)644-650(1998).
Barth, F., and Rinaldi-Carmona, M. The development of cannabinoid antagonists. Curr Med Chem6745-755(1999).
Di Marzo, V. Targeting the endocannabinoid system: To enhance or reduce?Nat Rev Drug Discov7438-455(2008).
Portier, M., Rinaldi-Carmona, M., Pecceu, F., et al. SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist. J Pharmacol Exp Ther288(2)582-589(1999).
Iwamura, H., Suzuki, H., Ueda, Y., et al. In vitro and in vivo pharmacological characterization of JTE-907, a novel selection ligand for cannabinoid CB2 receptor. J Pharmacol Exp Ther296(2)420-425(2001).
Wright, K.L., Duncan, M., and Sharkey, K.A. Cannabinoid CB2 receptors in the gastrointestinal tract: A regulatory system in states of inflammation. Br J Pharmacol153263-270(2008).